[-] Show simple item record

dc.contributor.authorKane, Erin Purtelleng
dc.contributor.authorFagan, Heather Bittnereng
dc.contributor.authorWolf, Diane G.eng
dc.date.issued2007eng
dc.description.abstractYes. B ased on current evidence, fluoxetine is the most effective selective serotonin reuptake inhibitor (SSRI) for treatment of major depressive disorder in adolescents. It is the only agent approved by the US Food and Drug Administration (FDA) for use in children (strength of recommendation [SOR]: A, based on meta-analysis of RCTs). All SSRI medications increase the risk of suicidal behavior in adolescents, but do not increase the risk of completing suicide (SOR: A, based on meta-analysis of RCTs).eng
dc.identifier.urihttp://hdl.handle.net/10355/3630eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2007 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 56, no. 09 (September 2007): 759-760eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectdepressive disordereng
dc.subjectsuicidal behavioreng
dc.subjectmorbidityeng
dc.subjectcognitive behavioral therapyeng
dc.subject.lcshFluoxetineeng
dc.subject.lcshDepression in adolescence -- Treatmenteng
dc.subject.lcshAdolescent psychotherapyeng
dc.titleShould we use SSRIs to treat adolescents with depression?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record